Hideki Kawanishi

Dr. Hideki Kawanishi

Tsuchiya General Hospital, Hiroshima 730-8655, Japan
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2015 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
YWYuzo Watanabe
Yuzo Watanabe
HKHideki Kawanishi
Hideki Kawanishi
KSKazuyuki Suzuki
Kazuyuki Suzuki
SNShigeru Nakai
Shigeru Nakai
KTKenji Tsuchida
Kenji Tsuchida
JMJun Minakuchi
Jun Minakuchi

1 April 2005 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
HKHideki Kawanishi
Hideki Kawanishi
HWHiroshi Watanabe
Hiroshi Watanabe
MMMisaki Moriishi
Misaki Moriishi
STShinichiro Tsuchiya
Shinichiro Tsuchiya
♦ Background: Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis (PD). The mortality rate for EPS has been high, primarily because of complications related to bowel obstruction. Also, therapeutic guidelines for EPS have not yet been established. In our hospital, favorable postoperative results were obtained in 50 patients whose EPS was treated surgically. ♦ Patients: All patients had chronic glomerulonephritis as the underlying kidney disease. All had undergone PD for between 29 months and 220 months (average: 113.9 months). During the course of PD, 3 patients developed EPS and were subsequently transferred to hemodialysis (HD). The other 47 patients (94.0%) developed EPS after discontinuation of PD. The reasons for transfer to HD were inadequate ultrafiltration (26 patients), bacterial peritonitis (16 patients), hypoalbuminemia (2 patients), renal transplantation (3 patients), and occurrence of EPS (3 patients). ♦ Intervention: At laparotomy, a definitive diagnosis of EPS was established in all patients by the presence of clumped intestine cocooned with a dense sclerotic membrane. In all cases, the small intestine was completely released by ablation of the capsules, resulting in resolution of the bowel obstruction symptoms. In 5 patients, the large intestine was ablated solely at the region of the sigmoid colon. The operating time varied from 3 hours to 18 hours (average: 6.9 hours). Oral food intake was initiated 5 – 60 days (average: 10.2 days) after surgery. ♦ Results: Perforation of the small intestine was detected postoperatively in 2 patients, who died 26 days and 37 days after surgery. The remaining 48 patients were followed for between 9 months and 107 months (average: 34.6 months). During follow-up, 6 – 12 months after the initial surgery, 4 patients experienced a recurrence of bowel obstruction symptoms that required a second laparotomy with enterolysis. Excluding the 2 patients with fatal outcomes, 46 patients (96%) experienced complete relief from bowel obstruction symptoms. The remaining 2 patients continued to experience mild, sub-acute bowel obstruction symptoms that could be successfully controlled solely by diet. ♦ Conclusions: Surgical treatment of 50 patients with EPS produced successful outcomes in all but 2 patients (96% success). Encapsulating peritoneal sclerosis should be actively treated by surgeons who genuinely understand this pathologic condition.

1 April 2005 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
HKHideki Kawanishi
Hideki Kawanishi
MMMisaki Moriishi
Misaki Moriishi
Since the first peritoneal dialysis (PD) patients with encapsulating peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered primarily a fatal complication. The incidence of EPS in PD patients has been reported to range from 0.7% to 7.3%, and the rate appears to be higher in patients receiving long-term treatment. The most recent data from Japan show an overall incidence of 2.5%, with a clear impact of extended PD duration, which also augments mortality. The incidence increases and the prognosis worsens with longer durations of PD. The incidences (and mortality rates) for EPS were 0% (0%), 0.7% (0%), 2.1% (8.3%), 5.9% (28.6%), 5.8% (61.5%), and 17.2% (100%) for patients who had undergone PD for 3, 5, 8, 10, 15, and >15 years respectively. Because EPS occurs after withdrawal from PD in more than half of patients with the condition, strict monitoring is necessary when a long-term patient is withdrawn from PD. Maintaining patients on standard PD for more than 8 years using conventional solutions is associated with a substantial risk for the development of EPS.

26 March 2009 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
HKHideki Kawanishi
Hideki Kawanishi
TATakashi Akiba
Takashi Akiba
IMIkuto Masakane
Ikuto Masakane
TTTadashi Tomo
Tadashi Tomo
MMMichio Mineshima
Michio Mineshima
TATadao Akizawa
Tadao Akizawa

1 June 2022 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
MLMark Lambie
Mark Lambie
JZJunhui Zhao
Junhui Zhao
KMKeith McCullough
Keith McCullough
SDSimon J. Davies
Simon J. Davies
HKHideki Kawanishi
Hideki Kawanishi
TCthe PDOPPS Steering Committee
the PDOPPS Steering Committee
Background and objectives: Quantifying contemporary peritoneal dialysis time on therapy is important for patients and providers. We describe time on peritoneal dialysis in the context of outcomes of hemodialysis transfer, death, and kidney transplantation on the basis of the multinational, observational Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) from 2014 to 2017. Design, setting, participants, & measurements: Among 218 randomly selected peritoneal dialysis facilities (7121 patients) in the PDOPPS from Australia/New Zealand, Canada, Japan, Thailand, the United Kingdom, and the United States, we calculated the cumulative incidence from peritoneal dialysis start to hemodialysis transfer, death, or kidney transplantation over 5 years and adjusted hazard ratios for patient and facility factors associated with death and hemodialysis transfer. Results: Median time on peritoneal dialysis ranged from 1.7 (interquartile range, 0.8–2.9; the United Kingdom) to 3.2 (interquartile range, 1.5–6.0; Japan) years and was longer with lower kidney transplantation rates (range: 32% [the United Kingdom] to 2% [Japan and Thailand] over 3 years). Adjusted hemodialysis transfer risk was lowest in Thailand, but death risk was higher in Thailand and the United States compared with most countries. Infection was the leading cause of hemodialysis transfer, with higher hemodialysis transfer risks seen in patients having psychiatric disorder history or elevated body mass index. The proportion of patients with total weekly Kt/V ≥1.7 at a facility was not associated with death or hemodialysis transfer. Conclusions: Countries in the PDOPPS with higher rates of kidney transplantation tended to have shorter median times on peritoneal dialysis. Identification of infection as a leading cause of hemodialysis transfer and patient and facility factors associated with the risk of hemodialysis transfer can facilitate interventions to reduce these events. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_05_31_CJN16341221.mp3

1 March 2006 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
HKHideki Kawanishi
Hideki Kawanishi
YHYasuki Hashimoto
Yasuki Hashimoto
HNHidetomo Nakamoto
Hidetomo Nakamoto
MNMasaaki Nakayama
Masaaki Nakayama
ATAnders Tranæus
Anders Tranæus